BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 828
Publisher
MDPI AG
Online
2020-04-01
DOI
10.3390/cancers12040828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of recurrence and metastasis in BRCA1/BRCA2 ‐associated breast cancers
- (2019) Yun Song et al. CANCER
- Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
- (2018) Séverine Guiu et al. BRITISH JOURNAL OF CANCER
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer
- (2018) D.Gareth R. Evans et al. AMERICAN JOURNAL OF HUMAN GENETICS
- The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
- (2018) Xinxin Zhu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
- (2018) Marcelo Sobral-Leite et al. OncoImmunology
- Genetic Versus Epigenetic BRCA1 Silencing Pathways
- (2017) Tingting Sun et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- ID4 controls luminal lineage commitment in normal mammary epithelium and inhibitsBRCA1function in basal-like breast cancer
- (2016) Laura A Baker et al. ENDOCRINE-RELATED CANCER
- Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient
- (2016) Feng-Feng Cai et al. Oncotarget
- MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression
- (2016) Nerea Matamala et al. Oncotarget
- Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer
- (2016) Aruna Korlimarla et al. PLoS One
- Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers
- (2015) Meriem Boukerroucha et al. BMC CANCER
- Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer
- (2015) X. Zhu et al. BREAST CANCER RESEARCH AND TREATMENT
- Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer
- (2015) Nami Yamashita et al. Clinical Breast Cancer
- Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival
- (2015) Aye A. Thike et al. HISTOPATHOLOGY
- Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies
- (2015) Li Zhang et al. Scientific Reports
- The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
- (2014) J. L. Meisel et al. ANNALS OF ONCOLOGY
- Immunohistochemical Detection of BRCA-1 and BRCA-2 Expression in Human Breast and Ovarian Tumors
- (2014) Thomas R. Vorrius et al. JOURNAL OF HISTOTECHNOLOGY
- miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer
- (2014) Elisabetta Crippa et al. PLoS One
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
- (2013) Y. Xu et al. ANNALS OF ONCOLOGY
- BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
- (2013) William Jacot et al. BMC CANCER
- BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC
- (2013) T. Ignatov et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
- (2013) E H Lips et al. BRITISH JOURNAL OF CANCER
- Genetic Susceptibility to Triple-Negative Breast Cancer
- (2013) K. N. Stevens et al. CANCER RESEARCH
- Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
- (2013) A. Prat et al. ONCOLOGIST
- Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours
- (2013) Roy Milner et al. VIRCHOWS ARCHIV
- BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
- (2012) Karuna Garg et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation
- (2012) Yong Hannah Wen et al. BREAST CANCER RESEARCH AND TREATMENT
- BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
- (2012) Olafur A. Stefansson et al. Epigenetics
- BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression
- (2012) Amanjit Bal et al. VIRCHOWS ARCHIV
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- Adjuvant early breast cancer systemic therapies according to daily used technologies
- (2011) W. Jacot et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Down-regulation ofBRCA1expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers
- (2011) Amandine I. Garcia et al. EMBO Molecular Medicine
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Triple-Negative Breast Cancer
- (2010) Anthony D. Elias AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
- (2010) E. H. Lips et al. ANNALS OF ONCOLOGY
- Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
- (2010) Eun Yoon Cho et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Methylation profiles of hereditary and sporadic ovarian cancer
- (2010) Guus M Bol et al. HISTOPATHOLOGY
- BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
- (2010) Jurgen Veeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors
- (2008) Xuesong Liu et al. ANALYTICAL BIOCHEMISTRY
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
- (2008) M. C.U. Cheang et al. CLINICAL CANCER RESEARCH
- Expression of BRCA1 protein in breast cancer and its prognostic significance
- (2008) Emad A. Rakha et al. HUMAN PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now